No medication has been specifically approved by the FDA for Raynaud’s phenomenon, so every drug used to treat it is technically off-label. That said, several classes of medication have solid evidence behind them, and most people with moderate-to-severe Raynaud’s end up on at least one. Calcium channel blockers and phosphodiesterase-5 inhibitors are the two best-supported options, though the benefits are more modest than many patients expect. The treatment picture gets more interesting, and more complicated, when you factor in topical options, intravenous drugs reserved for severe cases, and a handful of surprising off-label agents.
Calcium Channel Blockers as the Usual First Step
If you see a doctor about Raynaud’s, the first prescription you receive will almost certainly be a calcium channel blocker, most commonly nifedipine. These drugs relax the smooth muscle in blood vessel walls, which counteracts the excessive constriction that drives Raynaud’s attacks. They have been the default choice for decades, and there is reasonable evidence that they help, though “help” deserves some qualification.
A Cochrane review of trials in primary Raynaud’s found that calcium channel blockers reduced attacks by roughly 1.7 fewer per week compared to placebo. That is a real benefit, but it is modest, and the review described the effect as “minimally effective.”1PubMed Central. Calcium channel blockers for primary Raynaud’s phenomenon For someone who has ten or more attacks a week during winter, cutting two of them may feel worthwhile but hardly transformative. A network meta-analysis looking at secondary Raynaud’s (the kind tied to autoimmune conditions like scleroderma) found that calcium channel blockers improved both the frequency and severity of attacks compared to placebo, though evidence quality was rated low.2The Lancet Rheumatology. Comparative efficacy and tolerability of pharmacological treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis
Side effects are a real issue. Nifedipine commonly causes headaches, flushing, dizziness, and ankle swelling, and in one small trial comparing it to iloprost in scleroderma patients, three out of eleven participants withdrew specifically because of side effects.3British Medical Journal. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud’s phenomenon in patients with systemic sclerosis: a double blind randomised study Many patients find they need to start at a low dose and slowly increase. Amlodipine, another calcium channel blocker, tends to be better tolerated than nifedipine but has less direct trial evidence behind it for Raynaud’s specifically.
PDE5 Inhibitors
Phosphodiesterase-5 inhibitors, the drug class that includes sildenafil (Viagra) and tadalafil (Cialis), work by boosting nitric oxide signaling in blood vessels, promoting dilation. Nitric oxide is one of the key molecules that goes wrong in Raynaud’s: people with the condition tend to have reduced nitric oxide availability, contributing to excessive vasoconstriction.4Nature Reviews Rheumatology. The pathogenesis, diagnosis and treatment of Raynaud phenomenon
The same network meta-analysis that evaluated calcium channel blockers found PDE5 inhibitors effective for the frequency, severity, and duration of attacks in secondary Raynaud’s, making them one of only two drug classes to show significant benefits across all three of those outcomes.5The Lancet Rheumatology. Comparative efficacy and tolerability of pharmacological treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis In a pilot study of scleroderma patients with digital ulcers, sildenafil treatment reduced the average number of ulcers from about three per patient at baseline to less than one, with significant improvements in pain and Raynaud’s symptom scores.6PubMed Central. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study
The catch is tolerability. PDE5 inhibitors carry a notably higher rate of adverse events and dropouts compared to placebo. That same network meta-analysis reported that the odds of a serious adverse event or early withdrawal from a trial were over three times higher on PDE5 inhibitors than on placebo, a rate similar to what calcium channel blockers showed.7The Lancet Rheumatology. Comparative efficacy and tolerability of pharmacological treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis Headaches, flushing, and gastrointestinal symptoms are common. In practice, many clinicians add a PDE5 inhibitor when calcium channel blockers alone are not enough, rather than using it as a standalone first choice.
Topical Nitrates for Localized Relief
For people who cannot tolerate oral medications or prefer to avoid systemic side effects, topical nitroglycerin is an option worth knowing about. Applied directly to the fingers, nitroglycerin ointment delivers nitric oxide locally to dilate blood vessels. An early controlled study showed that applying nitroglycerin ointment significantly increased finger blood flow, with the treated hand showing a greater response than the untreated one.8PubMed. Topical nitroglycerin ointment in Raynaud’s phenomenon
A meta-analysis pooling seven placebo-controlled trials found a moderate-to-large treatment effect overall. Interestingly, the benefit was larger for secondary Raynaud’s than for primary Raynaud’s, which is the opposite of what calcium channel blockers tend to show.9PubMed. A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud’s phenomenon A trial of a newer nitroglycerin gel formulation (MQX-503) also demonstrated significant improvement in Raynaud’s severity scores compared to placebo.10PubMed. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial
The main downside is headaches, which happen because some of the nitroglycerin absorbs into the bloodstream even when applied to the skin. That same early study noted a drop in blood pressure and cardiac output alongside the local effects, confirming that the drug does not stay entirely local.11PubMed. Topical nitroglycerin ointment in Raynaud’s phenomenon Still, for many patients the headaches are milder than what oral vasodilators produce, and the convenience of treating only the affected fingers is appealing.
Why Primary and Secondary Raynaud’s Respond Differently
One pattern that runs through the evidence is that medications do not work equally well for primary Raynaud’s (where there is no underlying disease) and secondary Raynaud’s (where it is driven by scleroderma or another connective tissue disease). The reasons matter for setting expectations.
A Cochrane review that included both types found that calcium channel blockers reduced attacks by roughly three per week in both groups, with no statistically significant difference. However, when it came to attack severity, the picture changed: calcium channel blockers reduced severity significantly more in primary Raynaud’s than in secondary, a difference that reached statistical significance.12Cochrane Database of Systematic Reviews. Calcium channel blockers for primary and secondary Raynaud’s phenomenon In the nifedipine-specific subgroup, the drug clearly reduced severity in primary Raynaud’s but showed virtually no benefit over placebo in the secondary type.13Cochrane Database of Systematic Reviews. Calcium channel blockers for primary and secondary Raynaud’s phenomenon
This makes biological sense. In secondary Raynaud’s, the blood vessels themselves are structurally damaged by the underlying autoimmune disease. The problem is not just excessive constriction that can be chemically reversed; the vessel walls are thickened, scarred, and sometimes narrowed permanently. A drug that relaxes smooth muscle can only do so much when the plumbing itself is compromised. This is why people with secondary Raynaud’s often need more aggressive treatment strategies, including combinations of drugs or intravenous therapies.
Prostanoids for Severe and Refractory Cases
When oral medications fail or when digital ulcers are threatening tissue loss, intravenous prostanoids become the next line of defense. Iloprost, a synthetic prostacyclin analog, is the best studied. In a multicenter placebo-controlled trial of scleroderma patients, iloprost infusions reduced the number of Raynaud’s attacks by about 39% (compared to 22% with placebo) and improved a global severity score by about 35%.14PubMed. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study A Cochrane review confirmed that intravenous iloprost reduces the frequency and severity of attacks and helps heal digital ulcers, with effects that persist after the infusion period ends.15PubMed Central. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis
A protocol using cyclic iloprost infusions (given repeatedly at intervals rather than just once) showed not only clinical improvement but a meaningful boost in quality of life for scleroderma patients.16PubMed. Iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol The problem is access and cost. Iloprost infusions typically require multiple hours in a clinic or hospital and must be repeated regularly. In the United States, intravenous prostanoid therapy for Raynaud’s is often not covered by insurance, making it cost-prohibitive for routine use despite being included in every major international guideline.17PubMed Central. Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States
Endothelin Receptor Antagonists and Digital Ulcers
Bosentan, an oral drug that blocks the action of endothelin-1 (a potent vasoconstrictor), occupies a specific niche: preventing new digital ulcers in scleroderma patients. Two major randomized trials (RAPIDS-1 and RAPIDS-2) showed that bosentan reduced the number of new ulcers by roughly 30-48% over the treatment period.18PubMed. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist19PubMed Central. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial Patients who already had ulcers when they started treatment saw the greatest benefit, with new ulcer formation cut roughly in half.
An important distinction: bosentan prevented new ulcers but did not speed the healing of existing ones. This means it is more of a maintenance strategy than a rescue therapy. It also requires regular liver function monitoring because of potential hepatotoxicity. For this reason, bosentan tends to be reserved for patients with recurrent digital ulcers who have already tried other approaches.
Fluoxetine and Losartan as Off-Label Alternatives
Two drugs from unrelated therapeutic areas have shown surprising promise for Raynaud’s. Fluoxetine, best known as an antidepressant (Prozac), was compared head-to-head with nifedipine in a controlled trial. Both drugs reduced attack frequency and severity, but the improvement reached statistical significance only in the fluoxetine group.20PubMed. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine The mechanism likely involves serotonin’s role in platelet aggregation and vascular tone. The same network meta-analysis ranked selective serotonin reuptake inhibitors as superior to placebo for attack severity in secondary Raynaud’s, though the evidence was rated very low quality.21The Lancet Rheumatology. Comparative efficacy and tolerability of pharmacological treatments for secondary Raynaud’s phenomenon: a systematic review and network meta-analysis This is not enough to make fluoxetine a standard recommendation, but it is worth knowing about if you already take it for another reason or if you cannot tolerate conventional options.
Losartan, an angiotensin II receptor blocker commonly prescribed for high blood pressure, also showed strong results in a trial of primary Raynaud’s. Researchers described it as “highly effective” in reducing the number of vasospastic episodes.22PubMed. The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud’s phenomenon For someone who has Raynaud’s alongside high blood pressure, losartan could address both problems with a single pill. The evidence base is limited to small trials, so it has not made it into most guidelines as a primary recommendation.
Botulinum Toxin Injections
Injecting botulinum toxin (Botox) around the digital arteries of the hand is an emerging treatment that has gained traction for refractory cases. The idea is that Botox blocks the sympathetic nerve signals that trigger vasospasm. In a prospective study of twenty scleroderma patients, 80% reported overall symptom improvement, with significant gains in grip strength and hand function scores.23PubMed. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma
A three-year follow-up study confirmed sustained benefits, with significant reductions in pain and weekly episodes. Among patients who had digital ulcers at baseline, five out of seven healed completely within three months, and about two-thirds of all patients rated their overall satisfaction above 8 out of 10.24PubMed Central. Botulinum toxin type A in the treatment of Raynaud’s phenomenon: A three-year follow-up study Another series using a dorsal injection approach found that 88% of patients reported symptom improvement at six weeks, with 80% noting reduced cold intolerance.25PubMed. Optimisation of botulinum toxin type a treatment for the management of Raynaud’s phenomenon using a dorsal approach: a prospective case series
The main limitation is that most of the evidence comes from open-label studies without placebo controls, which means the placebo effect (and the powerful psychology of receiving an injection) could account for some of the benefit. Still, the consistency of the results and the durability of the response make this a credible option when medications have failed, and it avoids the systemic side effects of oral drugs.
Medications That Can Cause or Worsen Raynaud’s
Before adding a Raynaud’s medication to your regimen, it is worth checking whether something you already take is making things worse. A systematic review identified twelve classes of drugs that can trigger Raynaud’s episodes. Beta-blockers are the classic culprit, but the highest risk was actually associated with chemotherapy agents like cisplatin and bleomycin. More recently, tyrosine kinase inhibitors used in cancer treatment have been flagged as well.26PubMed Central. Drug-induced Raynaud’s phenomenon: beyond β-adrenoceptor blockers
ADHD medications deserve a specific mention because they affect a younger population that might not be screened for vascular side effects. A systematic review found that stimulant medications for ADHD can provoke Raynaud’s symptoms, though most cases were mild and resolved after stopping the medication or switching to a different one. In rare cases involving patients who had an underlying connective tissue disease, the consequences were far more serious, including ulceration and even tissue loss requiring amputation.27PubMed. Raynaud Syndrome Associated with Medication for Attention-Deficit/Hyperactivity Disorder: A Systematic Review If you or your child develops color changes in the fingers after starting a stimulant, it is worth raising with a doctor rather than waiting it out.
Raynaud’s in Specific Populations
Raynaud’s of the nipple during breastfeeding is an underrecognized cause of severe pain that is sometimes misdiagnosed as thrush or poor latch. Nifedipine has been used safely in this context; very little of the drug passes into breast milk, and in a case series of six mothers who chose to try it, all experienced prompt pain relief with only one developing side effects.28PubMed. Raynaud’s phenomenon of the nipple: a treatable cause of painful breastfeeding
In children, the same stepped approach applies as in adults: lifestyle measures first, then calcium channel blockers for moderate cases, and escalation to prostanoids or PDE5 inhibitors for severe disease. Surgery (digital sympathectomy) is a last resort reserved for cases that fail all drug therapies.29Reumatología Clínica. Raynaud’s Phenomenon in Children Pediatric dosing is largely extrapolated from adult data, and most treatment decisions are made by pediatric rheumatologists on a case-by-case basis.
The Insurance and Access Problem in the United States
The absence of any FDA-approved drug for Raynaud’s creates a cascade of practical problems. Every prescription a doctor writes is off-label, which does not prevent insurance from covering it in most cases for oral drugs, but creates significant barriers for expensive therapies. Intravenous prostanoids, which are recommended in every published international guideline for severe cases, are often simply out of reach for American patients because insurers will not cover them for an unapproved indication.30PubMed Central. Rethinking Strategies for a Pharmaceutical Approach to Pain Related to Connective Tissue–Related Raynaud Phenomenon in the United States
This gap between what the evidence supports and what patients can actually access is one of the most frustrating aspects of Raynaud’s care. In Europe, iloprost is more widely available and routinely used in specialist centers. American patients with severe secondary Raynaud’s sometimes end up cobbling together combinations of cheaper oral medications that produce a fraction of the benefit they could get from a single course of prostanoid infusions. Clinical trials of oral prostacyclin analogs, including treprostinil, are exploring whether an oral formulation could bridge this gap, though earlier attempts raised concerns about tolerability.
Supplements and Complementary Approaches
Given the limitations and side effects of prescription medications, it is natural to wonder about supplements. The most studied is Ginkgo biloba. One double-blind placebo-controlled trial found that a ginkgo extract reduced the number of Raynaud’s attacks per week by 56%, compared to 27% with placebo, a statistically significant difference.31PubMed. The use of Ginkgo biloba in Raynaud’s disease: a double-blind placebo-controlled trial That sounds impressive, but a broader meta-analysis of complementary and alternative therapies for Raynaud’s found no significant differences for the nutritional supplements that were studied overall.32Rheumatology. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis The positive ginkgo result is essentially one trial, and single trials in small samples are notoriously unreliable for supplements.
Fish oil, evening primrose oil, and various antioxidants have all been tried without consistent evidence of benefit. The honest read is that no supplement has enough data to recommend it as a substitute for proven medications, but ginkgo is the most plausible candidate for further study. If you want to try it alongside standard treatment, it is unlikely to cause harm, but tell your doctor, because ginkgo can interact with blood-thinning medications.
The Molecular Targets Shaping Future Drugs
Understanding why current drugs produce only moderate effects requires looking at the biology. The vascular spasm in Raynaud’s is not driven by a single pathway. Cooling activates alpha-2c adrenergic receptors on vascular smooth muscle cells through a signaling chain that involves reactive oxygen species and a pathway called Rho/Rho kinase. At the same time, endothelin-1 levels are elevated, nitric oxide production is reduced, and platelets are more prone to clumping.33PubMed. Understanding, assessing and treating Raynaud’s phenomenon Current drugs each target only one piece of this network: calcium channel blockers work on smooth muscle calcium channels, PDE5 inhibitors boost nitric oxide signaling, bosentan blocks endothelin. No single drug addresses the full picture.
Pilot trials of Rho kinase inhibitors and alpha-2c receptor antagonists have shown encouraging early results, directly targeting what appears to be the upstream trigger of excessive cold-induced constriction.34PubMed. Understanding, assessing and treating Raynaud’s phenomenon These are still years from routine clinical use, but they represent a shift toward targeting the root signaling defect rather than generally relaxing blood vessels. For now, the practical reality is that most patients manage Raynaud’s with a combination of lifestyle modifications and one or two medications, titrated to the best balance between benefit and side effects that they can tolerate.